Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | President | April 16, 2026 | April 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date April 16, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Other · Disposed 454,583 · Balance 0 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 491,803 |
Ending reported balance
After 2026-04-20 transaction · row 3
2 source rows · reconciled sequenceRow 2 · 2026-04-20 · Other · Acquired 454,583 · Balance 454,583 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. Row 3 · 2026-04-20 · Grant · Acquired 37,220 · Balance 491,803 F2: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-04-15 | Direct | 163,358 |
Reported balance
After 2026-04-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-16 · Grant · Acquired 163,358 · Balance 163,358 F3: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2031-04-20 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-20 · Other · Disposed 29,357 · Balance 0 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2031-04-20 | Direct | 29,357 |
Reported balance
After 2026-04-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-20 · Other · Acquired 29,357 · Balance 29,357 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.28 · Expires 2032-02-15 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-20 · Other · Disposed 8,726 · Balance 0 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.28 · Expires 2032-02-15 | Direct | 8,726 |
Reported balance
After 2026-04-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-20 · Other · Acquired 8,726 · Balance 8,726 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2034-04-16 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-20 · Other · Disposed 10,686 · Balance 0 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F5: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2034-04-16 | Direct | 10,686 |
Reported balance
After 2026-04-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-20 · Other · Acquired 10,686 · Balance 10,686 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F5: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2035-01-15 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-20 · Other · Disposed 206,782 · Balance 0 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F6: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2035-01-15 | Direct | 206,782 |
Reported balance
After 2026-04-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-04-20 · Other · Acquired 206,782 · Balance 206,782 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F6: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2035-01-15 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-04-20 · Other · Disposed 8,532 · Balance 0 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F7: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2035-01-15 | Direct | 8,532 |
Reported balance
After 2026-04-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-04-20 · Other · Acquired 8,532 · Balance 8,532 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F7: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2035-04-08 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-04-20 · Other · Disposed 5,775 · Balance 0 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F8: Twenty-five percent of the shares subject to the option vest on January 1, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2035-04-08 | Direct | 5,775 |
Reported balance
After 2026-04-20 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-04-20 · Other · Acquired 5,775 · Balance 5,775 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F8: Twenty-five percent of the shares subject to the option vest on January 1, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-01-14 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-04-20 · Other · Disposed 16,333 · Balance 0 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F9: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-01-14 | Direct | 16,333 |
Reported balance
After 2026-04-20 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-04-20 · Other · Acquired 16,333 · Balance 16,333 F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F9: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
F2: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
F3: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
F4: Fully vested.
F5: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date.
F6: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.
F7: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date.
F8: Twenty-five percent of the shares subject to the option vest on January 1, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
F9: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 16,333 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 18 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,333 Underlying: Common Stock · 16,333 shares Expires 2036-01-14 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F9 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 16,333 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 17 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 16,333 shares Expires 2036-01-14 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F9 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 5,775 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 16 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,775 Underlying: Common Stock · 5,775 shares Expires 2035-04-08 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F8 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on January 1, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 5,775 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 15 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 5,775 shares Expires 2035-04-08 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F8 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on January 1, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 8,532 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 14 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,532 Underlying: Common Stock · 8,532 shares Expires 2035-01-15 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F7 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 8,532 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 13 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 8,532 shares Expires 2035-01-15 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F7 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 206,782 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 12 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,782 Underlying: Common Stock · 206,782 shares Expires 2035-01-15 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F6 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 206,782 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 11 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 206,782 shares Expires 2035-01-15 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F6 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 10,686 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 10 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,686 Underlying: Common Stock · 10,686 shares Expires 2034-04-16 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 10,686 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 9 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 10,686 shares Expires 2034-04-16 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 8,726 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 8 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,726 Underlying: Common Stock · 8,726 shares Expires 2032-02-15 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 8,726 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 7 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 8,726 shares Expires 2032-02-15 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 29,357 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 6 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,357 Underlying: Common Stock · 29,357 shares Expires 2031-04-20 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 29,357 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 5 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 29,357 shares Expires 2031-04-20 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | GrantCommon Stock | 37,220 | $0.00 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · nonDerivative · entry 3 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 491,803 F2 · kind: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherCommon Stock | 454,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · nonDerivative · entry 2 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454,583 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F1 · price: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherClass B Common Stock | 454,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · nonDerivative · entry 1 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F1 · price: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. Read SEC document |
| April 16, 2026 Filed Apr 21, 2026 00:35 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | GrantStock Option (Right to Buy) · Derivative | 163,358 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0002126704-26-000004 · form4-04212026_120426.xml · derivative · entry 4 White Timothy Ogden · CIK 0002126704 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,358 Underlying: Common Stock · 163,358 shares Expires 2036-04-15 F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.